Monday, March 11, 2013
Sequestration will cut a $209
million hole in FDA's FY13 budget, but a chaotic budget process caused
by Congress's inability to pass a stable budget makes it impossible to know how
much funding the agency actually will have for the rest of this year or next
year. The combination of known cuts and budget uncertainty are likely to result
in drug review delays, according to FDA Commissioner Margaret Hamburg.
Hamburg last week told
BioCentury the agency cannot predict how many reviews will be delayed or the
length of delays.